Skip to content Skip to footer

Navigating Carbapenemase-Producing Enterobacterales (CPE) Screening Challenges in Modern Healthcare

Carbapenemase-producing Enterobacterales (CPE) continue to pose significant public health threats, increasing operational and economic pressures for Integrated Care Systems and NHS Trusts. The UK Health Security Agency advises the usage of locally developed risk assessments for identifying high-risk individuals for screening and determining appropriate testing methods – a process that is not without its difficulties. In response to these challenges, a diverse team of cross-specialty experts convened to explore practical strategies for incorporating the UK Health Security Agency framework within operational and clinical routines. The team identified four key patient groups for CPE screening, which included high-risk unplanned admissions, high-risk elective admissions, patients in high-risk units, and previously identified positive contacts.

Given the prominence of CPE, prompt and efficient detection is crucial. Rapid molecular testing was identified by the group as an advantageous screening method due to faster results and superior accuracy in comparison to conventionally employed culture-based testing. As our healthcare landscape continues to evolve in the aftermath of a global pandemic, it’s essential to take prompt action and utilize learnings gleaned from COVID-19 testing as well as past CPE outbreaks.

Moving forward, it becomes crucial to develop and implement bespoke CPE screening protocols, which take into account local epidemiology and unique risk factors. Constant analysis of local epidemiology, routine prevalence studies, and preparedness in the face of potential resource escalation in response to increased prevalence, clusters, or outbreaks – is key.

Furthermore, the growing prevalence of CPE infections, which in turn limits the availability of effective, low-toxicity, and affordable treatment options, is cause for serious concern. Unarguably, successful prevention of CPE outbreaks will have a long-term positive impact on operational flow, patient outcomes, and healthcare resource management.

Preventing and managing CPE outbreaks also reflect a multitude of economical implications, as the costs are borne not just for long hospital stays and expensive control measures, but also for the delayed or cancelled elective procedures, opportunity costs, and expensive anti-infective treatments.

The true extent of the CPE threat can only be understood through proactive detection and surveillance measures. Modern screening methods like molecular methods, such as PCR, have been recognized for their standardization, accuracy, speed, and specificity in identifying targeted microorganisms.

The collaborative efforts of a multitude of healthcare professionals are imperative for the successful rollout of a screening program. It is the assurance of such integrated partnerships within the healthcare system, alongside proactive detection, effective use of innovative testing techniques, and adherence to local and international directives that will power the fight against CPE and ensure continued delivery of the highest standards of healthcare.


Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]